This trial is active, not recruiting.

Condition metastatic melanoma
Treatment tyrosinase, mage-3, gntv
Phase phase 2
Sponsor Charite University, Berlin, Germany
Start date March 2003
End date September 2005
Trial size 25 participants
Trial identifier NCT00153569, HaemaCBFMM03


This trial assesses the clinical efficacy of a multiepitope peptide vaccine with GM-CSF and KLH as immunological adjuvants in stage IV melanoma patients

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Clinical efficacy
time frame:

Secondary Outcomes

Immune response
time frame:
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Metastatic melanoma - HLA-A1, -A2, -A24, -B44 Exclusion Criteria:

Additional Information

Official title Phase II Study of Multiepitope Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in Metastatic Melanoma
Principal investigator Ulrich Keilholz, MD
Trial information was received from ClinicalTrials.gov and was last updated in May 2010.
Information provided to ClinicalTrials.gov by Charite University, Berlin, Germany.